Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
about
Insulin resistance and skeletal muscle vasculature: significance, assessment and therapeutic modulatorsMetabolic actions of angiotensin II and insulin: a microvascular endothelial balancing actLong-term high-fat diet induces hippocampal microvascular insulin resistance and cognitive dysfunction.Liraglutide prevents microvascular insulin resistance and preserves muscle capillary density in high-fat diet-fed ratsVascular function, insulin action, and exercise: an intricate interplayCrossTalk proposal: De novo capillary recruitment in healthy muscle is necessary.Glucagon-like peptide 1 recruits muscle microvasculature and improves insulin's metabolic action in the presence of insulin resistanceAngiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptorGLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans.Globular adiponectin enhances muscle insulin action via microvascular recruitment and increased insulin deliveryLosartan increases muscle insulin delivery and rescues insulin's metabolic action during lipid infusion via microvascular recruitment.Protein kinase A mediates glucagon-like peptide 1-induced nitric oxide production and muscle microvascular recruitmentCandesartan acutely recruits skeletal and cardiac muscle microvasculature in healthy humans.Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanismAngiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivoInsulin regulates its own delivery to skeletal muscle by feed-forward actions on the vasculature.Regulation of muscle microcirculation in health and diabetes.Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα.Hypertension management and microvascular insulin resistance in diabetesRanolazine recruits muscle microvasculature and enhances insulin action in rats.Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation.The renin angiotensin aldosterone system and insulin resistance in humans.Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexiaNew insights into insulin action and resistance in the vasculature.Angiotensin inhibition and longevity: a question of hydration.Microvascular dysfunction: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension.Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.The renin-angiotensin system in the pathophysiology of type 2 diabetes.Arteriolar reactivity in lymphocyte-deficient mice.Rebuttal from Eugene J. Barrett, Michelle A. Keske, Stephen Rattigan and Etto C. Eringa.Direct Activation of the Angiotensin II Type-2 Receptors Enhances Muscle Microvascular Perfusion, Oxygenation and Insulin Delivery in Male Rats.Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment.Losartan Inhibits Vascular Calcification by Suppressing the BMP2 and Runx2 Expression in Rats In Vivo.Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice
P2860
Q28081458-EDB27051-8C53-493A-B8E2-D2C6A6FCEA85Q28390079-A86A0E01-E737-4F9F-A73F-8DE29D8A3258Q30275335-C7396EDF-B16F-4BA4-8B1E-872A1F6DB3D7Q30276321-B878515D-93F4-4F53-A982-51C9D30F6614Q30300466-BEFB09F8-E495-4592-9BA5-104EDFFA30F4Q30301224-6BE0DD5C-FDCE-4AFC-9F1C-F7962014285CQ30371576-A7C17484-174A-40BD-B719-4BDFFBC2F554Q30393746-7EE34EAE-D06D-47A7-8196-C57D8AF0F7F1Q30407530-D4FBA844-38AA-4B45-A9DF-4E1422B64DE6Q30413976-FBA87F8B-812F-4144-9F46-12C550D24111Q30414452-BB9A630D-260D-4F00-9813-EC7FB378EE41Q30415298-16B1ED42-EC71-4A6C-A358-D9EE91561A66Q30418516-F347CCA4-59DA-4902-BB35-79519808A941Q30421544-EA28A607-2CEB-4CF2-A1C2-5C81CB5ED73AQ30424204-1E8C7E6C-8BC7-4CC4-9D2F-B9CC365EE746Q30425679-5FE73251-0B27-4CFF-8C41-93C36A20ADA3Q30427254-AD0340B4-E58D-49E4-A573-E10319D36CDFQ30429023-A248D394-FF5E-4EF6-9E41-9F2EFD898557Q30433501-60C69600-ECD6-4526-89D8-8EC4CE59B187Q30456763-8B19F322-A9D0-4F57-A7AF-7C87FAE7EEA4Q34317509-7C5D41F0-F0EE-4ED3-8658-A6AAE946C99FQ36550987-2E8A53AA-B23A-4C84-A6A1-6B8C03EB4092Q37138465-93DA98E9-4D09-4583-AB6C-86CFD003687BQ37707789-D7AAD547-02F9-4844-AB16-3D3A5FB21D16Q37821796-86B1094B-1FA5-4C0E-9644-F11629033AC5Q37924914-04DCB7A4-F5E7-485A-827B-8C788C90E2F8Q37973874-4BABED40-FC91-4CAB-A02A-C8E4E1681696Q38044215-8EBBF228-751F-438E-ACF6-8B0451BBB114Q42491285-DD6ABE92-FA79-4155-AD94-D00BCBADFEB3Q45006348-7C0E86DB-FEDD-4F11-9848-5C745D594518Q45074259-FB5FB399-E2AA-4E47-B3FE-CA180B3ECF24Q47108613-B1E242F2-0CC2-43B6-8F5C-49C8C59DC765Q53535795-60A5B035-4F63-4DD7-AF90-1343EA625A54Q58699775-6A965E5B-5FA3-4A8A-A640-349068214AF5
P2860
Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Angiotensin II type 1 and type ...... scular volume and glucose use.
@ast
Angiotensin II type 1 and type ...... scular volume and glucose use.
@en
type
label
Angiotensin II type 1 and type ...... scular volume and glucose use.
@ast
Angiotensin II type 1 and type ...... scular volume and glucose use.
@en
prefLabel
Angiotensin II type 1 and type ...... scular volume and glucose use.
@ast
Angiotensin II type 1 and type ...... scular volume and glucose use.
@en
P2093
P2860
P1433
P1476
Angiotensin II type 1 and type ...... scular volume and glucose use.
@en
P2093
Eugene J Barrett
Robert M Carey
Weidong Chai
Wenhong Cao
Wenhui Wang
Zhenqi Liu
P2860
P304
P356
10.1161/HYPERTENSIONAHA.109.145409
P407
P577
2009-12-07T00:00:00Z